Evidence-Based Approach to MenopausePostmenopausal Hormone Therapy and Cardiovascular Disease in PerspectiveHodis, Howard N., MD* †; Mack, Wendy J., PhD† ‡Author Information *Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology, Department of Medicine and Preventive Medicine, Molecular Pharmacology and Toxicology ‡Department of Preventive Medicine †Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles, California Correspondence: Howard N. Hodis, MD, Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology, Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 132, Los Angeles, CA 90033. E-mail: firstname.lastname@example.org Clinical Obstetrics and Gynecology: September 2008 - Volume 51 - Issue 3 - p 564-580 doi: 10.1097/GRF.0b013e318181de86 Buy Metrics Abstract The totality of data indicate that the window of opportunity for reducing mortality and coronary heart disease is initiation of hormone therapy (HT) within 6 years of menopause and/or by 60 years of age and continued for 6 years or more. Additionally, the risks of HT are rare (<1/1000) especially in younger postmenopausal women and comparable with other primary prevention therapies. In fact, as randomized controlled trial results accumulate, the more they look like the consistent observational data. These studies showed that young postmenopausal women with menopausal symptoms who use HT for long periods of time have lower rates of mortality and coronary heart disease than comparable postmenopausal women who do not use HT. © 2008 Lippincott Williams & Wilkins, Inc.